Drug Profile

Amicidin beta - Macro Biologics

Alternative Names: Amicidin-β; Amicidin-β/EF; Amicidin-β/EF - Macro Biologics

Latest Information Update: 04 Mar 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Macro Biologics
Class Antibacterials; Antifungals; Polymers; Recombinant proteins; Surfactants
Mechanism of Action Undefined mechanism

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

04 Feb 2026 Preclinical trials in Wound infections in USA (Topical, Controlled release) before February 2026 (Macro Biologics pipeline, February 2026)
02 Feb 2026 Macro Biologics plans a phase I trial for Wound infections (Topical) in February 2026 (NCT07379684)
26 Apr 2022 Amicrobe has patent protection for compositions and uses of locally applied antimicrobials with enhanced performance and safety in USA

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com